Navigation Links
Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria

ANNAPOLIS, Md., Feb. 24 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that new data from the Company's Valortim® anthrax anti-toxin program were presented at the 8th Annual ASM Biodefense and Emerging Diseases Research Meeting, held in Baltimore, Maryland, February 21-24, 2010.

The data were presented by Dr. Alan S. Cross, Professor of Medicine and Dr. Subhendu Basu, Assistant Professor, University of Maryland School of Medicine, in a poster presentation entitled Human Adaptive Immune Response to Bacillus Anthracis.  

Valortim® is a fully human anti-toxin monoclonal antibody being developed for the prevention and treatment of inhalational anthrax.  Preclinical studies suggest that Valortim® has the potential to provide protection against anthrax infection when administered prophylactically (prior to the emergence of symptoms of anthrax infection) and also may increase survival when administered therapeutically (once symptoms become evident).

Previous data presented by Drs. Cross and Basu have shown that in addition to inhibiting anthrax toxin, Valortim® appears to augment the immune system's ability to kill anthrax bacilli by enhancing the human dendritic cell response to a challenge with anthrax spores.  These new data expand upon these observations by showing that Valortim® also enhances the human T cell response to B. anthracis. In addition to Valortim's established toxin-neutralizing function, which has been previously described, these studies indicate that it may also assist in enhancing the adaptive immune response to anthrax, which may lead to a reduction and clearance of the bacteria in the host organism.

Dr. Cross remarked, "Our latest research using human immune cells provides additional evidence of the role Valortim® may play in enhancing the elimination of B. anthracis to potentially minimize the severity of infection.  We hypothesize that Valortim® may protect against lethal anthrax infection by its toxin neutralization activity that allows the development of a potent adaptive immune response that facilitates the elimination of harmful bacteria in a host organism."

David P. Wright, President and Chief Executive Officer of PharmAthene, commented, "Drs. Cross and Basu continue to make excellent progress demonstrating how Valortim® may interact with the immune system to potentially minimize the extent and severity of infection with bacillus anthracis.  These data, combined with the accumulating non-clinical efficacy results in animal models, continue to show how Valortim® may have important differentiating benefits, which, if confirmed, may make it a strong choice for procurement consideration in the Strategic National Stockpile."  

The work reported by Drs. Cross and Basu is supported by the Maryland Industrial Partnerships Program (MIPS). The MIPS program was developed to accelerate the commercialization of technology in Maryland by jointly funding collaborative R&D projects between companies and University System of Maryland faculty.

About Valortim®

Valortim® is a fully human monoclonal antibody designed to protect against and treat anthrax infection, including inhalational anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium.  The investigational antibody is designed to target a protein component known as the anthrax Protective Antigen (PA) of the lethal toxin complex produced by the bacterium.  Preclinical studies suggest that Valortim® has the potential to provide significant protection against anthrax infection when administered prophylactically post-exposure (i.e., prior to the emergence of symptoms of anthrax infection) and also may increase survival when administered therapeutically (i.e., once symptoms become evident).

Anti-toxins such as Valortim® are a key element in combating and treating anthrax infection, in addition to vaccines and antibiotics.  The Department of Health and Human Services has issued a requirement for up to 200,000 anthrax anti-toxin treatments to be included in the Strategic National Stockpile and PharmAthene believes that Valortim® is well positioned to address this need.

About Anthrax

According to the Centers for Disease Control and Prevention, anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in hoofed mammals and can also infect humans. Symptoms of disease vary depending on how the disease is contracted, but usually occur within seven days after exposure. The serious forms of human anthrax are inhalation anthrax, cutaneous anthrax, and intestinal anthrax. Initial symptoms of inhalation anthrax infection may resemble a common cold. After several days, the symptoms may progress to severe breathing problems and shock. Inhalation anthrax is often fatal, even if treated by antibiotics.  Currently, antibiotics are the only drugs available for therapeutic or prophylactic use for inhalation anthrax, and post-exposure prophylaxis is the only FDA-approved indication for such products.  However, antibiotic therapy, while useful, is believed to be associated with a number of limitations, including: (1) lack of activity against the toxins produced by the B. anthracis bacteria, (2) need for long-term dosing to achieve full protection, complicated by side effects and non-compliance (3) lack of efficacy when administered late in the anthrax disease cycle, and (4) lack of effectiveness against multi-drug resistant or genetically engineered strains of anthrax.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax™ - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia® - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

For more information about PharmAthene, please visit

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements.  Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements.  PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements.  Risks and uncertainties include risks associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, and/or process validation of manufacturing processes for our product candidates, unexpected  determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Form 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC").  In particular, significant additional non-clinical animal studies, human clinical trials, and manufacturing development work remain to be completed for Valortim®.  At this point there can be no assurance that Valortim® will be shown to be safe and effective and approved by regulatory authorities for use in humans.  Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at

SOURCE PharmAthene, Inc.

Back to top



SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
2. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
3. Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
4. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
5. Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day
6. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
7. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
8. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
9. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
10. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
11. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
Post Your Comments:
(Date:10/9/2015)... , October 9, 2015 /PRNewswire/ ... --> The report summarizes ... and overall status of the manufacturers ... guidance and direction for companies and ... . --> ...
(Date:10/9/2015)... PHILADELPHIA , October 9, 2015 ... Conference, Oct. 7-9   ... information products and services, today launched ClinicalKey for Nursing ... authoritative content, tailored to meet the unique needs of nursing ... in Atlanta , Oct. 7-9, will have ...
(Date:10/9/2015)... 2015  Hi-Tech Pharmaceuticals ("Hi-Tech"), a leading global ... iForce Nutrition ("iForce"), one of the fastest-growing Sports Nutrition ... , today announced that they have entered into ... to acquire iForce. The transaction will enhance Hi-Tech,s ... through iForce,s strong distribution network. Jared ...
Breaking Medicine Technology:
... BETHLEHEM, Pa., April 28, 2011 Particle Sciences ... EVA Performance Polymers, a leading supplier of ethylene ... together to streamline the development of drug-eluting devices. ... Celanese EVA Performance Polymers are working to provide ...
... A new study published online today in The ... (Avastin) is as effective as ranibizumab (Lucentis), the current ... degeneration (AMD). The results are from ... a pioneering comparative effectiveness trial made possible through funding ...
Cached Medicine Technology:
(Date:10/10/2015)... ... 10, 2015 , ... Well-known Eastern Pennsylvania personal injury law ... The National Law Journal for inclusion in their second annual list of America’s ... States who obtained the largest awards for their personal injury clients in 2014-2015. ...
(Date:10/9/2015)... ... October 09, 2015 , ... The American ... Dean for Graduate Medical Education J. Michael Finley, DO, as the recipient of ... selected for his impact on graduate medical education opportunities for osteopathic residents, and ...
(Date:10/9/2015)... Aliso Viejo, CA (PRWEB) , ... October 09, 2015 , ... ... and easily add color pop grades to footage. A LUT is a Lookup Table ... color to the corresponding color indicated by the table. This pack comes with 60 ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... Smoke alarms ... smoke alarms can cut the risk of dying in reported home fires in half. ... to make sure smoke alarms are property installed and maintained. , Half of home ...
(Date:10/9/2015)... Emeryville, CA (PRWEB) , ... October 09, 2015 , ... ... Training Center for the elite developmental camp at the Karolyi Ranch in Huntsville, Texas ... camp,” Katreece Stone, Head Over Heels girls team head coach and executive director, said. ...
Breaking Medicine News(10 mins):
... education (PE) in schools is one of the main ... childhood obesity, and PE-related injuries are on the rise. ... also increase the risk of injury. While recognizing that ... combating obesity, parents and school administrators should remain vigilant ...
... , , EAST BRUNSWICK, N.J., Aug. ... announced that the Company has received a complete response letter from ... can not at this time approve the Company,s Biologics License Application ... patients refractory to conventional therapy. , , ...
... simplex virus-2 (HSV-2), which causes genital herpes, increases the ... the genital skin sores and breaks that often result ... an immune-cell environment conducive to HIV infection that persists ... after they have been treated with oral doses of ...
... , , MANCHESTER, England, Aug. 2 ... turning to cosmetic surgery in increasing numbers, driven by the recent ... , Male cosmetic surgery rates are not only ... attached to male cosmetic surgery has all but disappeared, but in ...
... , , , CHICAGO, July ... AOC ), the leading global provider of risk management ... System, Agribusiness and Beverage Industry Report . The first annual ... these industries remain abreast of emerging issues and learn how peers ...
... FRANCISCO (August 1, 2009)Patients with second primary lung cancers ... cancer (OPLC), are more likely to have localized disease ... to receive surgical treatment rather than radiation treatment. However, ... specific mortality, Fox Chase Cancer Center researchers reported today ...
Cached Medicine News:
CDIs new improved Implant Stabilizer has super-soft elastic bands with lace trim....
Bras and Breast Support...
Post-Surgical compression garments...
... The Albumin Cobalt Binding (ACB®) Test is ... Modified Albumin (IMA®) by measuring the cobalt ... serum sample. First identified in the early ... comes in contact with ischemic tissue in ...
Medicine Products: